Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von OldOrangeEyes 

QIAGEN NV diskutieren

QIAGEN NV

WKN: A2DKCH / Symbol: QGEN / Name: QIAGEN / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /

40,47 €
-0,15 %

Buy QIAGEN NV

Sell QIAGEN NV

Sell QIAGEN NV

Buy QIAGEN NV

Sell QIAGEN NV

Qiagen (NYSE: QGEN) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating.
Ratings data for QGEN provided by MarketBeat

Qiagen (NYSE: QGEN) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock.
Ratings data for QGEN provided by MarketBeat

Einschätzung Buy
Rendite (%) 12,02 %
Kursziel 56,74
Veränderung
Endet am 26.09.24

Qiagen (NYSE: QGEN) had its "buy" rating re-affirmed by analysts at Citigroup Inc.. They now have a $60.00 price target on the stock.
Ratings data for QGEN provided by MarketBeat

Einschätzung Buy
Rendite (%) 13,95 %
Kursziel 47,31
Veränderung
Endet am 17.10.24

Qiagen (NYSE: QGEN) had its price target lowered by analysts at JPMorgan Chase & Co. from $55.00 to $50.00. They now have an "overweight" rating on the stock.
Ratings data for QGEN provided by MarketBeat

Einschätzung Buy
Rendite (%) 7,35 %
Kursziel 46,33
Veränderung
Endet am 07.12.24

Qiagen (NYSE: QGEN) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $50.00 price target on the stock.
Ratings data for QGEN provided by MarketBeat

Einschätzung Buy
Rendite (%) 8,41 %
Kursziel 45,68
Veränderung
Endet am 20.12.24

Qiagen (NYSE: QGEN) had its price target raised by analysts at JPMorgan Chase & Co. from $45.00 to $50.00. They now have an "overweight" rating on the stock.
Ratings data for QGEN provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 55,66
Veränderung
Endet am 08.02.25

Qiagen (NYSE: QGEN) had its price target lowered by analysts at Citigroup Inc. from $61.86 to $60.00. They now have a "buy" rating on the stock.
Ratings data for QGEN provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 48,24
Veränderung
Endet am 08.02.25

Qiagen (NYSE: QGEN) had its price target raised by analysts at JPMorgan Chase & Co. from $50.00 to $52.00. They now have an "overweight" rating on the stock.
Ratings data for QGEN provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 47,44
Veränderung
Endet am 16.02.25

Qiagen (NYSE: QGEN) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $51.00 price target on the stock, up previously from $49.48.
Ratings data for QGEN provided by MarketBeat